Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.

被引：2
|
作者：
Sadetsky, Natalia
Chuo, Ching-Yi
Davidoff, Amy J.
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e18194
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18194
引用
收藏
页数：1
相关论文
共 50 条
  • [41] What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer
    LeBlanc, Thomas W.
    Nickolich, Myles
    Rushing, Christel N.
    Samsa, Gregory P.
    Locke, Susan C.
    Abernethy, Amy P.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (12) : 3455 - 3463
  • [42] Commentary in response to Carrigan et al: "An Evaluation of the Impact of Missing Deaths on Overall Survival Analyses of Advanced Non-small Cell Lung Cancer Patients Conducted in an Electronic Health Records Database"
    Wang, Shirley V.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (05) : 582 - 583
  • [43] An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database (vol 28, pg 572, 2019)
    Carrigan, G.
    Whipple, S.
    Taylor, M. D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (09) : 1278 - 1279
  • [44] A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
    Ott, Patrick A.
    Hu-Lieskovan, Siwen
    Chmielowski, Bartosz
    Govindan, Ramaswamy
    Naing, Aung
    Bhardwaj, Nina
    Margolin, Kim
    Awad, Mark M.
    Hellmann, Matthew D.
    Lin, Jessica J.
    Friedlander, Terence
    Bushway, Meghan E.
    Balogh, Kristen N.
    Sciuto, Tracey E.
    Kohler, Victoria
    Turnbull, Samantha J.
    Besada, Rana
    Curran, Riley R.
    Trapp, Benjamin
    Scherer, Julian
    Poran, Asaf
    Harjanto, Dewi
    Barthelme, Dominik
    Ting, Ying Sonia
    Dong, Jesse Z.
    Ware, Yvonne
    Huang, Yuting
    Huang, Zhengping
    Wanamaker, Amy
    Cleary, Lisa D.
    Moles, Melissa A.
    Manson, Kelledy
    Greshock, Joel
    Khondker, Zakaria S.
    Fritsch, Ed
    Rooney, Michael S.
    DeMario, Mark
    Gaynor, Richard B.
    Srinivasan, Lakshmi
    CELL, 2020, 183 (02) : 347 - +
  • [45] Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients
    Weberpals, Janick
    Becker, Tim
    Schmich, Fabian
    Ruettinger, Dominik
    Theis, Fabian
    Bauer-Mehren, Anna
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 585 - 586
  • [46] Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice
    Drakaki, Alexandra
    Dhillon, Preet K.
    Wakelee, Heather
    Chui, Stephen Y.
    Shim, Jinjoo
    Kent, Matthew
    Degaonkar, Viraj
    Hoang, Tien
    McNally, Virginia
    Luhn, Patricia
    Gutzmer, Ralf
    CANCER RESEARCH, 2020, 80 (16)
  • [47] CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
    Felip, Enriqueta
    Ardizzoni, Andrea
    Ciuleanu, Tudor
    Cobo, Manuel
    Laktionov, Konstantin
    Szilasi, Maria
    Califano, Raffaele
    Carcereny, Enric
    Griffiths, Richard
    Paz-Ares, Luis
    Duchnowska, Renata
    Alonso Garcia, Miriam
    Isla, Dolores
    Jassem, Jacek
    Appel, Wiebke
    Milanowski, Janusz
    Van Meerbeeck, Jan P.
    Wolf, Juergen
    Li, Ang
    Acevedo, Angelic
    Popat, Sanjay
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 160 - 172
  • [48] BIOMARKER DEVELOPMENT FOR A PHASE II STUDY OF COMBINATION EPIGENETIC THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Wrangle, John M.
    Juergens, Rosalyn A.
    Vendetti, Frank
    Coleman, Barbara
    Sebree, Rosa
    Rudek, Michelle
    Herman, James
    Rudin, Charles
    Brock, Malcolm V.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1101 - S1101
  • [49] Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study
    Bonanno, L.
    Zulato, E.
    Attili, I.
    Pavan, A.
    Del Bianco, P.
    Nardo, G.
    Verza, M.
    Pasqualini, L.
    Pasello, G.
    Zago, G.
    Frega, S.
    Fassan, M.
    Calabrese, F.
    Amadori, A.
    Guarneri, V.
    Conte, P. F.
    Indraccolo, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 649 - 649
  • [50] Evaluation of treatment adherence, persistance, and quality of life in patients with advanced non-small cell lung cancer (ANSCLC) treated with erlotinib (e) as second-line therapy
    Gebbia, V.
    Russo, P.
    Mancuso, G.
    Arcara, C.
    Borsellino, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 547 - 547
12345